Literature DB >> 3381603

[Immunochemical analysis of the immune response in late manifestations of Lyme borreliosis].

B Wilske1, V Preac-Mursic, G Schierz, W Gueye, P Herzer, K Weber.   

Abstract

Compared to American strains, European Borrelia burgdorferi strains revealed considerable heterogeneity of major proteins. Four strains isolated from ticks, human skin and human CSF were selected from our 23 Borrelia burgdorferi isolates. These strains and the American type strain B31 were characterized by SDS-PAGE (Coomassie Blue staining) and Western blots (using rabbit immune sera against two of the strains and two monoclonal antibodies (H5323 and H3TS) against a major outer surface protein (OspA]. The strains showed considerable differences in SDS-PAGE pattern. Corroborating the results of a previous study, we could demonstrate that the OspA (31/32K) can change from a minor to a major protein and in reverse the pC (21/22K) from a major to a minor protein during subculturing. Moreover, European strains can antigenically differ in OspA, pC and also in a further low molecular weight protein of 17/18K. To examine whether the antigenic heterogeneity of European isolates is reflected in the immune response of European patients we examined sera from patients with late manifestations of Lyme Borreliosis by Western blot using the five strains as antigens. Sera from seven patients with acrodermatitis chronica atrophicans (ACA) showed a surprisingly strong reactivity with the skin isolate. All sera had antibodies against the 17/18K protein of the skin isolate, but none was reactive with the analogous 17/18K of the other strains. On the other hand a comparable predominance of one strain was not found testing sera from patients with Lyme arthritis. One patient even had antibodies against OspA and OspB proteins of strain B31. Contrary to findings in American Lyme Disease antibodies against the OspA were rarely observed in the sera of our patients (only one patient had such antibodies) although we tested the patients sera with five different strains. Only two patients had stronger reactions with the skin isolate. These findings suggest that ACA is caused by antigenically closely related Borreliae. This could explain the finding that ACA is rarely observed in the US (US strains are antigenically closely related to strain B31). Our findings in patients with Lyme Arthritis--on the other hand--suggest that "different serotypes" can cause Lyme Arthritis. This does not exclude the possibility that Borrelia proteins are an important factor in the pathogenesis of Lyme arthritis. Finally the differences in reactivity of sera with different strains in the Western blot led us to examine whether such differences are also found in serodiagnostic tests using different strains as antigens.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3381603

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  27 in total

1.  Antibody response against autologous and heterologous isolates of Borrelia burgdorferi in four patients with Lyme neuroborreliosis.

Authors:  M Karlsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

2.  Surface exposure and species specificity of an immunoreactive domain of a 66-kilodalton outer membrane protein (P66) of the Borrelia spp. that cause Lyme disease.

Authors:  J Bunikis; L Noppa; Y Ostberg; A G Barbour; S Bergström
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  Impact of strain heterogeneity on Lyme disease serology in Europe: comparison of enzyme-linked immunosorbent assays using different species of Borrelia burgdorferi sensu lato.

Authors:  U Hauser; H Krahl; H Peters; V Fingerle; B Wilske
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues.

Authors:  Gereon Goettner; Ulrike Schulte-Spechtel; Ruth Hillermann; Gabi Liegl; Bettina Wilske; Volker Fingerle
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  A flagella-less mutant of Borrelia burgdorferi. Structural, molecular, and in vitro functional characterization.

Authors:  A Sadziene; D D Thomas; V G Bundoc; S C Holt; A G Barbour
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Immunoblot using recombinant antigens derived from different genospecies of Borrelia burgdorferi sensu lato.

Authors:  B Wilske; V Fingerle; V Preac-Mursic; S Jauris-Heipke; A Hofmann; H Loy; H W Pfister; D Rössler; E Soutschek
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

7.  Cellular immune reactivity to recombinant OspA and flagellin from Borrelia burgdorferi in patients with Lyme borreliosis. Complexity of humoral and cellular immune responses.

Authors:  A Krause; G R Burmester; A Rensing; C Schoerner; U E Schaible; M M Simon; P Herzer; M D Kramer; R Wallich
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Characterization of Finnish Borrelia burgdorferi sensu lato isolates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and with monoclonal antibodies.

Authors:  J Tuomi; L K Rantamäki; R Tanskanen; J Junttila
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

9.  Genetic polymorphism of the gene encoding the outer surface protein A (OspA) of Borrelia burgdorferi.

Authors:  G Zumstein; R Fuchs; A Hofmann; V Preac-Mursic; E Soutschek; B Wilske
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

10.  Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species.

Authors:  G Will; S Jauris-Heipke; E Schwab; U Busch; D Rössler; E Soutschek; B Wilske; V Preac-Mursic
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.